Literature DB >> 8709248

Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction.

S Fruehling1, S K Lee, R Herrold, B Frech, G Laux, E Kremmer, F A Grässer, R Longnecker.   

Abstract

Epstein-Barr virus (EBV) recombinants which carry three different deletion mutations in the LMP2A cytoplasmic amino-terminal domain were constructed. The presence of each mutation, LMP2A delta 21-36, LMP2A delta 21-64, and LMP2A delta 21-85, in EBV-infected transformed lymphoblastoid cell lines was confirmed by PCR analysis and Southern blot hybridization. Confirmation of mutant LMP2A protein expression was by immunofluorescence and immunoblotting with a newly identified rat monoclonal antibody that recognizes each of the LMP2A deletion mutations. Lymphoblastoid cell lines infected with recombinant EBV DNAs containing the mutations were analyzed for loss of LMP2A's dominant-negative effect on surface immunoglobulin signal transduction by monitoring induction of tyrosine phosphorylation, calcium mobilization, and activation of lytic replication following surface immunoglobulin cross-linking. Domains of LMP2A important for induction of tyrosine phosphorylation, calcium mobilization, and activation of lytic replication were identified.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8709248      PMCID: PMC190646          DOI: 10.1128/JVI.70.9.6216-6226.1996

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential.

Authors:  R Longnecker; C L Miller; X Q Miao; A Marchini; E Kieff
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  An Epstein-Barr virus transformation-associated membrane protein interacts with src family tyrosine kinases.

Authors:  A L Burkhardt; J B Bolen; E Kieff; R Longnecker
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

3.  SH2 domains recognize specific phosphopeptide sequences.

Authors:  Z Songyang; S E Shoelson; M Chaudhuri; G Gish; T Pawson; W G Haser; F King; T Roberts; S Ratnofsky; R J Lechleider
Journal:  Cell       Date:  1993-03-12       Impact factor: 41.582

Review 4.  Nonreceptor tyrosine protein kinases.

Authors:  J B Bolen
Journal:  Oncogene       Date:  1993-08       Impact factor: 9.867

5.  Mutants of Epstein-Barr virus with a selective marker disrupting the TP gene transform B cells and replicate normally in culture.

Authors:  O J Kim; J L Yates
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

Review 6.  Proteins with SH2 and SH3 domains couple receptor tyrosine kinases to intracellular signalling pathways.

Authors:  T Pawson; P Olivier; M Rozakis-Adcock; J McGlade; M Henkemeyer
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1993-06-29       Impact factor: 6.237

7.  An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking.

Authors:  C L Miller; J H Lee; E Kieff; R Longnecker
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

8.  Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes.

Authors:  C L Miller; R Longnecker; E Kieff
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

9.  Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B.

Authors:  R Longnecker; C L Miller; B Tomkinson; X Q Miao; E Kieff
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

10.  Characterization of the antibody response to the latent infection terminal proteins of Epstein-Barr virus in patients with nasopharyngeal carcinoma.

Authors:  B Frech; U Zimber-Strobl; T T Yip; W H Lau; N Mueller-Lantzsch
Journal:  J Gen Virol       Date:  1993-05       Impact factor: 3.891

View more
  47 in total

Review 1.  The genetic approach to the Epstein-Barr virus: from basic virology to gene therapy.

Authors:  H J Delecluse; W Hammerschmidt
Journal:  Mol Pathol       Date:  2000-10

2.  Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt.

Authors:  F Scholle; K M Bendt; N Raab-Traub
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway.

Authors:  R Swart; I K Ruf; J Sample; R Longnecker
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  C-terminal domain of the Epstein-Barr virus LMP2A membrane protein contains a clustering signal.

Authors:  L Matskova; I Ernberg; T Pawson; G Winberg
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

5.  PY motifs of Epstein-Barr virus LMP2A regulate protein stability and phosphorylation of LMP2A-associated proteins.

Authors:  M Ikeda; A Ikeda; R Longnecker
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

6.  Identification of the novel K15 gene at the rightmost end of the Kaposi's sarcoma-associated herpesvirus genome.

Authors:  J K Choi; B S Lee; S N Shim; M Li; J U Jung
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

7.  Epstein-Barr virus represses the FoxO1 transcription factor through latent membrane protein 1 and latent membrane protein 2A.

Authors:  Angharad M Shore; Paul C White; Rosaline C-Y Hui; Abdelkader Essafi; Eric W-F Lam; Martin Rowe; Paul Brennan
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

8.  An auto-regulatory loop for EBV LMP2A involves activation of Notch.

Authors:  Leah J Anderson; Richard Longnecker
Journal:  Virology       Date:  2007-11-05       Impact factor: 3.616

9.  A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.

Authors:  Christopher P Fox; Tracey A Haigh; Graham S Taylor; Heather M Long; Steven P Lee; Claire Shannon-Lowe; Simon O'Connor; Catherine M Bollard; Javeed Iqbal; Wing C Chan; Alan B Rickinson; Andrew I Bell; Martin Rowe
Journal:  Blood       Date:  2010-07-29       Impact factor: 22.113

10.  Role of the immunoreceptor tyrosine-based activation motif of latent membrane protein 2A (LMP2A) in Epstein-Barr virus LMP2A-induced cell transformation.

Authors:  Makoto Fukuda; Yasushi Kawaguchi
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.